Clinical Trials Logo
  1. Home
  2. Healthy
  3. NCT03934710
  4. Details
NCT03934710 Clinical Trial

Mood Effects of Serotonin Agonists Extended

Healthy Clinical Trial

— MESA-E  

Official title:
Mood Effects of Serotonin Agonists Extended

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT03934710
Other study ID # IRB18-1183
Secondary ID 5R01DA002812
Status Completed
Phase Phase 1
First received
Last updated
Start date April 20, 2019
Est. completion date June 7, 2021

Study information
Verified date November 2023
Source University of Chicago
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In this study we are examining the effects of repeated very low doses of serotonin agonists on mood individuals with negative mood.

Description:

Here, we are examining the effects of four repeated low doses of lysergic acid diethylamide (LSD), compared to placebo, administered to healthy adults at 3-4 day intervals, on mood, cognitive performance and responses to emotional tasks

Recruitment information / eligibility
Status Completed
Enrollment 56
Est. completion date June 7, 2021
Est. primary completion date June 7, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria: - English fluency - High school level education - BMI between 19 and 30 Exclusion Criteria: - Diagnosed medical condition - women who are nursing, pregnant, or plan to become pregnant within 3 months - History of psychotic disorder or family history of psychotic disorder

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• Placebo
Drug will be administered in solution form
• Serotonin agonist - 13ug
13ug lysergic acid diethylamide
• Serotonin agonist - 26ug
26ug lysergic acid diethylamide

Locations
Country Name City State
United States Matthew Bona Chicago Illinois

Sponsors (2)
Lead Sponsor Collaborator
University of Chicago National Institute on Drug Abuse (NIDA)

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary DASS-21 The primary outcome measure is the depression anxiety and stress scale (DASS) 21. This self-report measure contains 21 items and the range of scores for depression is 0-42, anxiety 0-42, and stress 0-42. Our primary outcome measure is total depression scale ratings during session 5, with lower scores indicating lower ratings of depression. End of session 5, approximately 2 weeks from baseline
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1